Inflammaging as a link between autoimmunity and cardiovascular disease: the case of rheumatoid arthritis
Pedro Santos-Moreno,
Adriana Rojas-Villarraga,
Gabriel Burgos-Angulo,
Maria Alejandra Martinez-Ceballos,
Alejandro Pizano,
Dario Echeverri,
Paula K Bautista-Niño,
Anton J M Roks
Affiliations
Pedro Santos-Moreno
Rheumatology, Biomab IPS, Bogota, Colombia
Adriana Rojas-Villarraga
1Clinical information group, Artmedica IPS, Medellín, Colombia
Gabriel Burgos-Angulo
Internal Medicine Department, Fundación Universitaria de Ciencias de la Salud (FUCS), Bogota, Cundinamarca, Colombia
Maria Alejandra Martinez-Ceballos
Research Division, Fundación Universitaria de Ciencias de la Salud (FUCS), Bogotá, Cundinamarca, Colombia
Alejandro Pizano
Vascular Function Research Laboratory and Department of Interventional Cardiology, Fundación Cardioinfantil Instituto de Cardiología, Bogota, Cundinamarca, Colombia
Dario Echeverri
Vascular Function Research Laboratory and Department of Interventional Cardiology, Fundación Cardioinfantil Instituto de Cardiología, Bogota, Cundinamarca, Colombia
Paula K Bautista-Niño
Research Center, Fundación Cardiovascular de Colombia, Floridablanca, Santander, Colombia
Anton J M Roks
Department of Internal Medicine, Division of Pharmacology and Vascular Medicine, Erasmus Medical Center Department of Internal Medicine, Rotterdam, South Holland, The Netherlands
Currently, traditional and non-traditional risk factors for cardiovascular disease have been established. The first group includes age, which constitutes one of the most important factors in the development of chronic diseases. The second group includes inflammation, the pathophysiology of which contributes to an accelerated process of vascular remodelling and atherogenesis in autoimmune diseases. Indeed, the term inflammaging has been used to refer to the inflammatory origin of ageing, explicitly due to the chronic inflammatory process associated with age (in healthy individuals). Taking this into account, it can be inferred that people with autoimmune diseases are likely to have an early acceleration of vascular ageing (vascular stiffness) as evidenced in the alteration of non-invasive cardiovascular tests such as pulse wave velocity. Thus, an association is created between autoimmunity and high morbidity and mortality rates caused by cardiovascular disease in this population group. The beneficial impact of the treatments for rheumatoid arthritis at the cardiovascular level has been reported, opening new opportunities for pharmacotherapy.